XML 35 R23.htm IDEA: XBRL DOCUMENT
v3.22.4

Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2022
Income Tax Disclosure [Abstract] |
Income Taxes | Note 13. Income Taxes We are subject to U.S. federal, state and foreign corporate income taxes. The provision (benefit) for income taxes is based on income (loss) before provision (benefit) for income taxes as follows (in thousands):
| Year Ended December 31,
| 2022 |  | 2021 |  | 2020
U.S. | $ | 766,781 |  |  | $ | 991,873 |  |  | $ | (16,609) |
Non-U.S. | (237,665) |  |  | (421,429) |  |  | (215,609) |
Income (loss) before provision (benefit) for income taxes | $ | 529,116 |  |  | $ | 570,444 |  |  | $ | (232,218) |
On a periodic basis, we reassess the valuation allowance on our deferred income tax assets. Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction-by-jurisdiction basis. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In the fourth quarter of 2021, we assessed the valuation allowance and considered positive evidence, including significant cumulative consolidated and U.S. income over the three years ended December 31, 2021, consistent growth in product revenues, and expectations regarding future profitability. We also assessed negative evidence, including the potential impact of competition, clinical failures and patent expirations on our projections. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that the majority of our U.S. deferred tax assets would be realized in the future and released the associated valuation allowance as of December 31, 2021. This resulted in a benefit of $569.0 million. As of December 31, 2022, we maintained a valuation allowance of $472.1 million against a portion of our remaining U.S. deferred tax assets as well as select state and foreign deferred tax assets. Our provision (benefit) for income taxes consists of the following (in thousands):
| Year Ended December 31,
| 2022 |  | 2021 |  | 2020
Current: |  |  |  |  |
Federal | $ | 90,088 |  | $ | 50,565 |  | $ | 43,595
State | 38,136 |  | 32,505 |  | 18,881
Foreign | 3,141 |  | 4,397 |  | 1,353
| 131,365 |  | 87,467 |  | 63,829
Deferred: |  |  |  |  |
Federal | 62,107 |  |  | (407,852) |  | —
State | (3,709) |  |  | (57,677) |  | — |
Foreign | (1,307) |  |  | (75) |  |  | (350) |
| 57,091 |  |  | (465,604) |  |  | (350) |
Total provision (benefit) for income taxes | $ | 188,456 |  |  | $ | (378,137) |  |  | $ | 63,479 |
A reconciliation of income taxes at the U.S. federal statutory rate to the provision (benefit) for income taxes is as follows (in thousands):
| Year Ended December 31,
| 2022 |  | 2021 |  | 2020
Provision (benefit) at U.S. federal statutory rate | $ | 111,114 |  | $ | 119,793 |  |  | $ | (48,766)
State and local income taxes | 26,767 |  | 34,461 |  |  | (21,637)
Foreign tax rate differential | 13,670 |  | 55,171 |  | 30,839
Income tax credits | (30,505) |  |  | (55,139) |  |  | (38,221) |
Change in valuation allowance | 67,056 |  |  | (523,279) |  | 158,815 |
Foreign-derived intangible income | (36,748) |  |  | (28,259) |  |  | (22,830) |
Stock based compensation | 19,704 |  | 15,497 |  | 2,802 |
Acquisitions accounted for as research and development expenses | 14,700 |  | — |  | — |
Other | 2,698 |  | 3,618 |  | 2,477
Provision (benefit) for income taxes | $ | 188,456 |  |  | $ | (378,137) |  | $ | 63,479
The foreign tax rate differential in the table above reflects the impact of operations in jurisdictions with tax rates that differ from the U.S. federal statutory rate of 21%. Significant components of our deferred tax assets and liabilities are as follows (in thousands):
| December 31,
| 2022 |  | 2021
Deferred tax assets: |  |  |
Net operating loss carry forwards | $ | 182,193 |  |  | $ | 137,935 |
Federal and state research credits | 17,141 |  |  | 206,184 |
Capitalized research and development | 265,140 |  |  | 59,247 |
Deferred revenue and accruals | 72,657 |  |  | 42,326 |
Non-cash compensation | 83,138 |  |  | 83,002 |
Acquisition-related contingent consideration | 30,483 |  |  | 31,450 |
Intangibles, net | 257,614 |  |  | 305,228 |
Long term investments | 54,662 |  |  | 34,733 |
Other | 9,600 |  |  | 15,991 |
Total gross deferred tax assets | 972,628 |  |  | 916,096 |
Less valuation allowance for deferred tax assets | (472,125) |  |  | (408,180) |
Net deferred tax assets | $ | 500,503 |  |  | $ | 507,916 |
Deferred tax liabilities: |  |  |
Property and equipment | $ | (33,683) |  |  | $ | (33,259) |
Other | (8,879) |  |  | (7,119) |
Total gross deferred tax liabilities | (42,562) |  |  | (40,378) |
Net deferred tax assets | $ | 457,941 |  |  | $ | 467,538 |
The valuation allowance for deferred tax assets increased by approximately $63.9 million during the year ended December 31, 2022, decreased by approximately $522.0 million during the year ended December 31, 2021. The net valuation allowance increase during 2022 was primarily due to the generation of future deductible temporary differences mainly associated with U.S. research and development expenses required to be capitalized and amortized under the Tax Cuts and Jobs Act of 2017, as well as foreign net operating losses (“NOLs”), which are not more-likely-than-not to be realized as of December 31, 2022. As of December 31, 2022, we had NOL carryforwards, research and development credit carryforwards and orphan drug tax credit carryforwards as follows (in thousands):
| Amount |  | Expiring if not utilized
Net operating loss carryforwards |  |  |
State | $ | 257,806 |  | 2023 through 2041; indefinite
Foreign | 1,692,283 |  | 2023 through 2029
Research and development credit carryforwards |  |  |
State | 20,773 |  | 2024 through 2042; indefinite
Orphan drug tax credit carryforwards | 14,641 |  | 2042
The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement. If such unrecognized tax benefits were realized, we would recognize a tax benefit of $61.2 million. The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):
| Year Ended December 31,
| 2022 |  | 2021
Balance at beginning of year | $ | 62,359 |  | $ | 31,597
Additions related to prior periods tax positions | 5,027 |  | 28,488
Reductions related to prior periods tax positions | (2,087) |  |  | (311) |
Additions related to current period tax positions | 8,290 |  | 3,042
Settlements | (104) |  |  | (95) |
Reductions due to lapse of applicable statute of limitations | (356) |  |  | (288) |
Currency translation adjustment | (89) |  |  | (74)
Balance at end of year | $ | 73,040 |  | $ | 62,359
Our policy is to recognize interest and penalties related to uncertain tax positions, if any, as a component of income tax expense. During the years ending December 31, 2022 and 2021, we recorded interest and penalties as a component of income tax expense of $3.8 million and $0.6 million, respectively. We do not anticipate any significant changes to our unrecognized tax benefits during the next twelve months. We file U.S. federal, state and local income tax returns and income tax returns in various foreign jurisdictions, with statutes of limitation generally ranging from three to five years during which such tax returns may be audited by the relevant tax authorities. Those statutes could be extended due to NOL or tax credit carryforwards generated during these periods that are subsequently utilized in open tax periods. In general, tax authorities have the ability to adjust the NOL carryforward or tax credits for three years after utilization of that year’s tax attribute carryforward.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 21 -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 17 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 14 -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 270 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -URI https://asc.fasb.org/topic&trid=2144680 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration